National Comprehensive Cancer Network

Members Only
NCCN Oncology Research Program (ORP)
NCCN and Pfizer Inc. Grant Opportunity - Submit by July 15, 2015
ORP Recent News
ORP Affiliate Research Consortium
ORP Scientific Publications
ORP for Industry
ORP Investigator Steering Committee
ORP Testimonials
Clinical Trials at NCCN Member Institutions
Find NCCN ORP Funded Clinical Trials at NCCN Member Institutions
ORP Grant History
Informed Consent Language Database
Points to Consider on the Best Practices for Biorepositories, Registries and Databases
ORP Disclosure Policy
NCCN Collaboration with the National Business Group on Health
NCCN Health Information Technology Licensees

NCCN Research & Business Resources

NCCN ORP Scientific Publications


Bibliography: NCCN Oncology Research Program Manuscripts

Bibliography: NCCN Oncology Research Program Abstracts



NCCN ORP Manuscripts


Bladder Cancer

Hussain M, Daignault S, Agarwal N, et al. A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma. Cancer. (2014) doi: 10.1002/cncr.28767
http://onlinelibrary.wiley.com/doi/10.1002/cncr.28767/abstract


Brain Cancer

Chamberlain MC & Johnston, SK. Salvage therapy with single agent bendamustine for recurrent glioblastoma. J Neuro-Oncol 2011;105:523–30.
http://www.ncbi.nlm.nih.gov/pubmed/21626071


Breast Cancer

Layman RM, Ruppert AS, Lynn M, et al. Severe and prolonged lymphopenia observed in patients treated with bendamustine and erlotinib for metastatic triple negative breast cancer. Cancer Chemother Pharmacol in press 2013;71:1183–1190.
http://link.springer.com/article/10.1007%2Fs00280-013-2112-2#

Reinbolt RE, Alam S, Layman R, et al. Pneumocystis jiroveci pneumonia in an atypical host.  Clin Breast Cancer 2012;12:138–141.
http://www.ncbi.nlm.nih.gov/pubmed/22133356

Lustberg MB, Povoski SP, Zhao W, et al. Phase II trial of neoadjuvant exemestane in combination with celecoxib in postmenopausal women who have breast cancer. Clin Breast Cancer 2011;11:221–227.
http://www.ncbi.nlm.nih.gov/pubmed/21729671

Moulder S, Valkov N, Neuger A, et al. Phase 2 study of gemcitabine and irinotecan in metastatic breast cancer with correlatives to determine topoisomerase I localization as a predictor of response. Cancer 2008;113:2646–2654.
http://onlinelibrary.wiley.com/doi/10.1002/cncr.23916/pdf

Mrozek E, Kolesar J, Young D, et al. Phase II study of sequentially administered low–dose mitomycin–C (MMC) and irinotecan (CPT–11) in women with metastatic breast cancer. Ann Oncol 2008;19:1417–1422.
http://annonc.oxfordjournals.org/content/early/2008/04/11/annonc.mdn154.full

O’Connor T, Rustum Y, Levine E & Creaven P. A phase I study of capecitabine and a modulatory dose of irinotecan in metastatic breast cancer. Cancer Chemother Pharmacol 2008;61:125–131.
http://www.springerlink.com/content/kw601j77145t6023/


Gastrointestinal Cancer

Petullo B, Wei L,Yereb M, et al. A phase II study of biweekly pralatrexate and docetaxel in patients with advanced esophageal and gastroesophageal carcinoma that have failed first-line platinum-based therapy. J Gastrointest Oncol 2015. doi: 10.3978/ j.issn.2078-6891.2015.011  
http://www.thejgo.org/article/view/4049

Uronis HE, Bendell JC, Altomare I, et al. A phase II study of capecitabine, oxaliplatin, and bevacizumab in the treatment of metastatic esophagogastric adenocarcinomas. Oncologist 2013;18:271–272.
http://www.ncbi.nlm.nih.gov/pubmed/23485624

Ko AH, Espinoza AM, Jones KA, et al. Optimizing the administration of fixed–dose rate gemcitabine plus capecitabine using an alternating–week schedule: a dose finding and early efficacy study in advanced pancreatic and biliary carcinomas. Am J Clin Oncol 2012;35:411–417.
http://www.ncbi.nlm.nih.gov/pubmed/21552099?log$=activity

Hill ME, Li X, Kim S, et al. A phase I study of the biomodulation of capecitabine by docetaxel and gemcitabine (mGTX) in previously untreated patients with metastatic adenocarcinoma of the pancreas. Cancer Chemother Pharmacol 2011;67:511–517.
http://www.springerlink.com/content/t241853g000514jv/

Weekes CD, Nallapareddy S, Rudek MA, et al. Thymidylate synthase (TYMS) enhancer region genotype–directed phase II trial of oral capecitabine for 2nd line treatment of advanced pancreatic cancer.  Invest New Drugs 2011;29:1057–1065.
http://www.springerlink.com/content/e13354576r8j1676/

Saif MW, Lansigan F, Ruta S, et al. Phase I study of the botanical formulation PHY906 with capecitabine in advanced pancreatic and other gastrointestinal malignancies. Phytomedicine 2010;17:161–169.
http://www.ncbi.nlm.nih.gov/pubmed/20092990?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum&ordinalpos=3

Burkitt K, Chun SY, Dang DT, & Dang LH. Targeting both HIF–1 and HIF–2 in human colon cancer cells improves tumor response to sunitinib treatment. Mol Cancer Ther 2009;8:1148–1156.
http://mct.aacrjournals.org/content/8/5/1148.long

George S, Merriam P, Maki GR, et al. Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas. J Clin Oncol 2009;27:3154–3160.
http://jco.ascopubs.org/cgi/content/abstract/27/19/3154

Javle M, Yu J, Garrett C, et al. Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: a phase II study. Br J Cancer 2009;100:1842–1845.
http://www.nature.com/bjc/journal/v100/n12/abs/6605099a.html

Jimeno A, Amador ML, Kulesza P, et al. Assessment of celecoxib pharmacodynamics in pancreatic cancer. Mol Cancer Ther 2006;5:3240–3247.
http://mct.aacrjournals.org/content/5/12/3240.full

General

He L, Grecula JC, Ling Y, et al. Development and validation of sensitive liquid chromatography/tandem mass spectrometry method for quantification of bendamustine in mouse brain tissue. J Chromatogr B 2012;905:141–144.
http://dx.doi.org/10.1016/j.jchromb.2012.08.013

Milind MJ, Cao S, Durrani AF, et al. Celecoxib and mucosal protection: Translation from an animal model to a phase I clinical trial of Celecoxib, Irinotecan, and 5-Fluorouracil. Clin Cancer Res 2007;13:965–971.
http://clincancerres.aacrjournals.org/content/13/3/965.full


Head and Neck Cancer

Fury MG, Sherman EJ, Rao SS, et al. Phase I Study of weekly nab-paclitaxel + weekly cetuximab + intensity-modulated radiation therapy (IMRT) in patients with stage III-IVB head and neck squamous cell carcinoma (HNSCC) Ann Oncol 2014 Mar;25(3):689-94. doi: 10.1093/annonc/mdt579. Epub 2014 Feb 3
http://www.ncbi.nlm.nih.gov/pubmed/24496920

Ho, AL, Lipson BL, Sherman EJ et al. A Phase II Study of Pralatrexate with Vitamin B12 and Folic Acid Supplementation for Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Cancer. Investigational New Drugs: February 25, 2014.
http://link.springer.com/article/10.1007/s10637-014-0073-x

Fury MG, Sherman E, Ho A, et al. A phase I study of temsirolimus plus carboplatin plus paclitaxel for patients with recurrent or metastatic (R/M) head and neck squamous cell cancer (HNSCC). Cancer Chemother Pharmacol 2012;70:121–128.
http://www.ncbi.nlm.nih.gov/pubmed/22644799

Fury MG, Sherman E, Lisa D, et al. A randomized phase II study of cetuximab every 2 weeks at either 500 or 750 mg/m2 for patients with recurrent or metastatic head and neck squamous cell cancer. JNCCN 2012;10:1391–1398.
http://www.ncbi.nlm.nih.gov/pubmed/23138167

Hepatocellular Carcinoma

Kelley RK, Nimeiri HS, Munster PN, et al. Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates. Ann Oncol 2013;00:1–8.
http://annonc.oxfordjournals.org/content/early/2013/03/20/annonc.mdt109.abstract

Zhang X, Louie A, Li X, et al. A Simple and sensitive LC–MS/MS method for simultaneous determination of temsirolimus and its major metabolite in human whole blood. Chromatographia 2012;75:1405–1413.
http://link.springer.com/content/pdf/10.1007%2Fs10337–012–2341–2

Fu S, Naing A, Moulder SL, et al. Phase I trial of hepatic arterial infusion of nanoparticle albumin–bound paclitaxel: toxicity, pharmacokinetics, and activity. Mol Cancer Ther 2011;10:1300–1307.
http://www.ncbi.nlm.nih.gov/pubmed/21571911

Melanoma

Johnson AS, Crandall H, Dahlman K, Kelley MC.  Preliminary Results from a Prospective Trial of Preoperative Combined BRAF and MEK-Targeted Therapy in Advanced BRAF Mutation-Positive Melanoma. J Am Coll Surg. 2015 Apr;220(4):581-593.e1. doi: 10.1016/j.jamcollsurg.2014.12.057. Epub 2015 Jan 30.
http://www.pubfacts.com/detail/25797743  

Lung Cancer

Komaki R, Wei X, Allen PK, et al. Phase I study of celecoxib with concurrent irinotecan, cisplatin, and radiation therapy for patients with unresectable locally advanced non-small cell lung cancer. Front. Oncol 2011;1:52.
http://www.frontiersin.org/Thoracic_Oncology/10.3389/fonc.2011.00052/abstract

Shao H, Tang H, Salavaggione OE, et al. Improved response to nab–paclitaxel compared with cremophor–solubilized paclitaxel is independent of secreted protein acidic and rich in cysteine expression in non–small cell lung cancer. J Thorac Oncol 2011;6:998–1005.
http://www.ncbi.nlm.nih.gov/pubmed/21532503


Prostate Cancer

Armstrong AJ, Shen T, Halabi S, et al. A phase II trial of Temsirolimus in men with castration-resistant metastatic prostate cancer. Clin Genitourin Cancer 2013;13:138–139.
http://www.ncbi.nlm.nih.gov/pubmed/23830964


Renal Cell Cancer

Bhatt RS, Wang X, et al. Renal cancer resistance to antiangiogenic therapy is delayed by restoration of angiostatic signaling. Mol Cancer Ther 2010;9:2793–2802.
http://mct.aacrjournals.org/content/9/10/2793.abstract

Rini BI, Weinberg V, Dunlap S, et al. Maximal COX-2 immunostaining and clinical response to celecoxib and interferon alpha therapy in metastatic renal cell carcinoma. Cancer 2006;106:566–575.
http://onlinelibrary.wiley.com/doi/10.1002/cncr.21661/full


Sarcoma

Thornton KA, Cheri AR, Trucco MM, et al. A dose-finding study of temsirolimus and liposomal doxorubicin for patients with recurrent and refractory bone and soft tissue sarcoma. Int J Cancer 2013;133:997–1005. http://www.ncbi.nlm.nih.gov/pubmed/23382028

Yoon SS, Stangenberg L, Jin-Lee Y, et al. Efficacy of Sunitinib and radiotherapy in genetically engineered mouse model of soft-tissue sarcoma. Int J Radiat Oncol Biol Phys 2009;74:1207–1216.
http://www.sciencedirect.com/science/article/pii/S0360301609003502


Solid Tumors

Wheler J, Kurzrock R, Falchook G, et al.  Phase I Combination of Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss Patients with Advanced Solid Tumors Refractory to Standard Therapy.    Invest New Drugs. 2015 Jun;33(3):700-9. doi: 10.1007/s10637-015-0238-2. Epub 2015 Apr 24. 
http://www.ncbi.nlm.nih.gov/pubmed/25902899

Pan E, Yu D, Zhao X, et al.  Phase I study of bendamustine with concurrent whole brain radiation therapy in patients with brain metastases from solid tumors.  J Neurooncol. 2014 Sep;119(2):413-20. doi: 10.1007/s11060-014-1510-6. Epub 2014 Jun 26.
http://www.ncbi.nlm.nih.gov/pubmed/24965340

Tsimberidou AM, Adamopoulos AM, Ye Y et al. Phase I Clinical Trial of Bendamustine and Bevacizumab for Patients with Advanced Cancer. J Natl Compr Canc Netw. 2014 Feb 1;12(2):194-203.
http://www.ncbi.nlm.nih.gov/pubmed/24586081

Twardowski PW, Smith-Powell L, Carroll M, et al. Biologic markers of angiogenesis: Circulating endothelial cells in patients with advanced malignancies treated on phase I protocol with metronomic chemotherapy and celecoxib. Cancer Invest 2008;26:53–59.
http://informahealthcare.com/doi/abs/10.1080/07357900701681541

Saif WM, Sellers S, Li M, et al. A phase I study of bi–weekly administration of 24­–h gemcitabine followed by 24–h irinotecan in patients with solid tumors. Cancer Chemother Pharmacol 2007;60:871–882.
http://link.springer.com/article/10.1007%2Fs00280–007–0434–7


Thyroid Cancer

Mrozek E, Kloos TR, Ringel DM, et al. Phase II study of celecoxib in metastatic differentiated thyroid carcinoma. J Clin Endocrinology & Metabolism 2006;91:2201–2204.
http://jcem.endojournals.org/content/91/6/2201.full



NCCN ORP Abstracts


Adenoid Cystic Carcinoma

Ho A, Sherman E, Fury M, et al. Phase II Study of Axitinib in Patients with Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma. Journal of Clinical Oncology Vol 32, No 15_suppl (May 20 Supplement), 2014: 6093 http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/6093


Brain Cancer

Elizabeth R. Gerstner E, Batchelor T, Rosen B, et al.  Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastoma.  J Clin Oncol 33, 2015 (suppl; abstr 2025).
http://abstracts.asco.org/156/AbstView_156_144582.html

Johnston SK, Graham C, Grimm S, et al.  Salvage therapy with single agent bendamustine for recurrent glioblastoma [abstract].  J Neuro-Oncol 2011;105:Abstract OT-04. 
http://connection.ebscohost.com/c/articles/67187338/salvage-therapy-single-agent-bendamustine-recurrent-glioblastoma

Johnston SK & Chamberlain MC.  Salvage therapy with single agent bendamustine for recurrent anaplastic glioma [abstract].  J Clin Oncol 2011;29:Abstract 12506.
http://meeting.ascopubs.org/gca?allch=&submit=Go&gca=ascomtg%3B29%2F15_suppl%2Fe12506

Grecula JC, Ammirati M, Kendra KL, et al.  Phase I study of bendamustine and fractionated stereotactic radiotherapy (FSRT) in patients with one to three brain metastases from solid malignancies [abstract].  J Clin Oncol 2010;28(Suppl 15):Abstract TPS146.
http://meeting.ascopubs.org/gca?allch=&submit=Go&gca=ascomtg%3B28%2F15_suppl%2FTPS146

Chamberlain MC, Graham C, Mrugala M & Johnston S.  Bendamustine for recurrent glioblastoma [abstract].  Society Neuro-Oncol  2010;12(Suppl 4):Abstract OT-11. 
http://neuro-oncology.oxfordjournals.org/content/12/suppl_4/iv69.abstract


Breast Cancer

Snider JS, Sachdev, JC, Allen, JW, et al. Pathologic complete response (pCR) with weekly nanoparticle albumin bound (nab-P) plus carboplatin (C) followed by doxorubicin plus cyclophosphamide (AC) with concurrent bevacizumab (B) for triple-negative breast cancer (TNBC). J Clin Oncol 2013;31Abstract 1068.
http://meetinglibrary.asco.org/content/117576-132

Sachdev JC, Snider J, Schwartzberg L, et al. Interim results for neoadjuvant bevacizumab with weekly nanoparticle albumin bound (nab)-paclitaxel plus carboplatin followed by doxorubicin plus cyclophosphamide (AC) in triple-negative breast cancer. J Natl Compr Canc Netw 2013;11:Abstract 2013–2.
http://www.jnccn.org/content/11/3/240.full

Snider JN, Allen JW, Young R, et al.  Neoadjuvant bevacizumab with weekly nanoparticle albumin bound (nab)-paclitaxel plus carboplatin followed by doxorubicin plus cyclophosphamide (AC) for triple negative breast cancer [abstract].  Cancer Res 2012;72(Suppl 3)Abstract OT3-3-07.
http://cancerres.aacrjournals.org/gca?gca=canres%3B72%2F24_Supplement%2FOT3-3-07&allch=&submit=Go

Snider JN, Young RR, Schwartzberg LS, et al. Neoadjuvant Bevacizumab with weekly Nanoparticle albumin bound (nab)-paclitaxel plus Carboplatin followed by Doxorubicin plus Cyclophosphamide (AC) for Triple Negative Breast Cancer. J Clin Oncol 2012; 30(15): Abstract TPS1137. http://meeting.ascopubs.org/cgi/content/abstract/30/15_suppl/TPS1137?sid=1edaaf0e-440d-45ec-98e7-fe1668fa3dd1

Specht JM, Kurlan BF, Dunnwald LK, et al. Dynamic FDG PET and DCE-MRI to assess tumor metabolism and blood flow in response to neoadjuvant sunitinib and paclitaxel followed by AC + G-CSF in patients with locally advanced (LABC) and/or inflammatory breast cancer (IBC) [abstract].  Cancer Res 2011;71(Suppl 3):Abstract P2-09-09.
http://cancerres.aacrjournals.org/content/71/24_Supplement/P2-09-09.abstract?maxtoshow=&hits=10&RESULTFORMAT=&author1=Specht%252C+J&titleabstract=DCE-MRI+and+dynamic+FDG+PET+&searchid=1&FIRSTINDEX=0&fdate=1/1/2000&tdate=1/31/2015&resourcetype=HWCIT

Gajria D, King TA, Pannu H, et al.  Combined inhibition of mTORC1 with temsirolimus and HER2 with neratinib: A phase I study in patients with metastatic HER2-amplified breast cancer [abstract].  J Clin Oncol 2011;29:Abstract 574.
http://meeting.ascopubs.org/gca?allch=&submit=Go&gca=ascomtg%3B29%2F15_suppl%2F574

Layman RM, Ruppert AS, Lynn M, et al.  Severe and prolonged lymphopenia observed In patients treated with bendamustine and erlotinib for metastatic triple negative breast cancer [abstract].  ASH Annual Meeting Abstracts 2010;116:Abstract 1739. https://ash.confex.com/ash/2010/webprogram/Paper33701.html

Sachdev JC, Kronish LE, West S, et al.  Neoadjuvant bevacizumab with weekly nanoparticle albumin bound nab-paclitaxel plus carboplatin followed by doxorubicin plus cyclophosphamide (AC) for triple-negative breast cancer [abstract].  J Clin Oncol 2010;28(Suppl 15):Abstract TPS100.
http://meeting.ascopubs.org/gca?allch=&submit=Go&gca=ascomtg%3B28%2F15_suppl%2FTPS100

Specht JM, Partridge S, Dunnwald L, et al.  DCE-MRI and dynamic FDG PET to monitor breast cancer response to neoadjuvant sunitinib in patients with locally-advanced breast cancer [abstract].  Cancer Res 2009;69(Suppl 1):Abstract 6006.
http://cancerres.aacrjournals.org/gca?gca=canres%3B69%2F2_Supplement%2F6006&allch=&submit=Go

Shapiro CL, Povoski SP, Jiminez R, et al.  Phase II trial of neoadjuvant exemestane [EXE] and celecoxib [CELE] in breast cancer: Results of biomarkers [abstract].  J Clin Oncol 2007;25(Suppl 18):Abstract 11056.
http://meeting.ascopubs.org/gca?allch=citmgr&gca=ascomtg%3B25%2F18_suppl%2F11056&submit=Go

Moulder SL, Valkov N, Gump J, et al.  Is cytoplasmic localization of topoisomerase I (topo I) a mechanism of resistance for topo I inhibitors? Results from an NCCN sponsored phase II trial of gemcitabine and irinotecan in metastatic breast cancer.  AACR Meeting Abstracts 2006:Abstract 1270-d-1271.
http://www.aacrmeetingabstracts.org/cgi/content/abstract/2006/1/1270-d

Moulder SL, Valkov N, Minton S, et al.  A single arm phase II trial of gemcitabine (G) and irinotecan (I) in metastatic breast cancer (MBC): can localization of topoisomerase I (topo I) predict response to topo I inhibitors?  J Clin Oncol 2006;24(Suppl 18):Abstract 661.
http://meeting.ascopubs.org/gca?allch=&submit=Go&gca=ascomtg%3B24%2F18_suppl%2F661

Twardowski PW, Smith-Powell L, Carrol M, et al.  Biologic markers of angiogenesis: circulating endothelial cells in patients with advanced malignancies treated on phase I protocol with metronomic chemotherapy and celecoxib [abstract].  AACR Meeting Abstracts 2006:412-b.
http://www.aacrmeetingabstracts.org/cgi/content/abstract/2006/1/412-b

Mrozek E, Kolesar J, Allen D, et al.  Phase II study of sequentially administered mitomycin (MMC) and irinotecan (CPT-11) in patients (pts) with metastatic breast cancer (MBC).  J Clin Oncol 2006;24(Suppl 18):Abstract 10542.
http://meeting.ascopubs.org/gca?allch=&submit=Go&gca=ascomtg%3B24%2F18_suppl%2F10542

Moulder SL, Munster P, Minton S, et al.  Results of a planned efficacy and safety analysis for a National Comprehensive Cancer Network sponsored phase II study of gemcitabine and irinotecan (GI) in metastatic breast cancer (MBC).  J Clin Oncol 2005;23(Suppl 16):Abstract 679.
http://meeting.ascopubs.org/gca?allch=&submit=Go&gca=ascomtg%3B23%2F16_suppl%2F679


Carcinoid Cancer

Cives M, Strosberg J, Campos T, et al.  A phase II study of Axitinib in advanced carcinoid tumors:  preliminary.  J Clin Oncol 33, 2015 (suppl; abstr 4100) 
http://abstracts.asco.org/156/AbstView_156_149839.html


Cholangiosarcoma

Azad S, Zinner R, Sartorius-Mergenthaler S, et al. Pazopanib (P) and trametinib (T) in advanced cholangiocarcinoma (CC): a Phase Ib study.  J Clin Oncol 33, 2015 (suppl; abstr 4072).
http://abstracts.asco.org/156/AbstView_156_145205.html


Gastrointestinal Cancer

Bekaii-Saab T, Kim R, McDonough S, et al.  SWOG S1310: Randomized phase II trial of single agent MEK inhibitor trametinib vs. 5-fluorouracil or capecitabine in refractory advanced biliary cancer.  J Clin Oncol 33, 2015 (suppl; abstr TPS4142). http://abstracts.asco.org/156/AbstView_156_150637.html

Malhotra U, Miller A, Bushunow PW, et al. A phase II trial of pralatrexate (P) plus oxaliplatin (O) in advanced esophagogastric cancer (aEGC). J Clin Oncol 33, 2015 (suppl 3; abstr 152) 
http://meetinglibrary.asco.org/content/140575-158

Kelley RK, Chang AN, Anguiano E et al. Next-generation sequencing (NGS) of serum microRNA in hepatocellular carcinoma (HCC) patients treated with sorafenib and an mTOR inhibitor. J Clin Oncol 32 2014 (suppl 3; abstr LBA204).
http://meetinglibrary.asco.org/content/123022-143

Chan E, Arlinghaus LR, Cardin DB, et al.  Phase I trial of chemoradiation with capecitabine and vorinostat in pancreatic cancer [abstract].  J Clin Oncol 2013;30(Suppl 34):Abstract 225.
http://meeting.ascopubs.org/gca?allch=&submit=Go&gca=ascomtg%3B31%2F4_suppl%2F225

Malhotra U, Miller A, Adjei A, et al. Pralatrexate (P) plus oxaliplatin (O) in advanced esophagogastric cancer: preliminary report of the safety lead-in cohort in a phase II trial. J Natl Compr Canc Netw 2013;11:Abstract 2013–15.
http://www.jnccn.org/content/11/4/373.full

Espinoza AM, Ko AH, Venook AP, et al.  A phase I study, with expanded cohort, of biweekly fixed-dose rate gemcitabine (FDR GEM) plus capecitabine (CAP) in patients with advanced pancreatic (APC) and biliary carcinomas (ABC) [abstract].  J Clin Oncol 2010;28(Suppl 15):Abstract 4136.
http://meeting.ascopubs.org/gca?allch=&submit=Go&gca=ascomtg%3B28%2F15_suppl%2F4136

Saif M, Li J, Lamb L, et al.  Phase II study of PHY906 plus capecitabine (CAP) in pts with gemcitabine-refractory pancreatic cancer (PC) and measurement of cytokines [abstract].  J Clin Oncol 2010;28:Abstract e14540.
http://meeting.ascopubs.org/gca?allch=&submit=Go&gca=ascomtg%3B28%2F15_suppl%2Fe14540

Weekes C, Nallapareddy S, Jimeno A, et al.  Single nucleotide polymorphisms of TSER, ATM, RecQ1 genes association with survival in pancrease cancer [abstract].  J Clin Oncol 2009;27:Abstract e14590.
http://meeting.ascopubs.org/gca?allch=&submit=Go&gca=ascomtg%3B27%2F15S%2Fe14590

Burkitt K, Chun S, Dang D, et al.   Sunitinib therapy is additive/synergistic with blockade of HIF-1 and -2 in colon cancer cells [abstract].  AACR Meeting Abstracts 2008:Abstract 4042.
http://www.aacrmeetingabstracts.org/cgi/content/meeting_abstract/2008/1_Annual_Meeting/4042?maxtoshow=&hits=10&RESULTFORMAT=&author1=dang&fulltext=Sunitinib+&andorexactfulltext=and&searchid=1&FIRSTINDEX=0&sortspec=relevance&resourcetype=HWCIT


General

Hammers H, Paesante S, Shen L, et al.  Combination of the VEGF receptor tyrosine kinase sunitinib and the mTOR inhibitor rapamycin leads to tumor regression in the RENCA model [abstract].  AACR Meeting Abstracts 2008:Abstract 1104.
http://www.aacrmeetingabstracts.org/cgi/content/meeting_abstract/2008/1_Annual_Meeting/1104?maxtoshow=&hits=10&RESULTFORMAT=&author1=hammers&andorexactfulltext=and&searchid=1&FIRSTINDEX=0&sortspec=relevance&resourcetype=HWCIT


Genitourinary Cancer

Alva AS, Argarwal N, Siefker-Radtke AO, et al.  Targeting epidermal growth factor receptor (EGFR) in urothelial cancer (UC): A phase II randomized trial of cisplatin (C) with gemcitabine (G) with or without cetuximab [abstract].  J Clin Oncol 2010;28(Suppl 15):Abstract TPS239. 
http://meeting.ascopubs.org/gca?allch=&submit=Go&gca=ascomtg%3B28%2F15_suppl%2FTPS239


Gynecologic Cancer

Matulonis U, Wright A, Collins S, et al.  A single arm, single stage phase II trial of trametinib (GSK1120212) and GSK2141795 in persistent or recurrent cervical cancer.   J Clin Oncol 33, 2015 (suppl; abstr TPS5618).  http://abstracts.asco.org/156/AbstView_156_152134.html


Head and Neck Cancer

Chung C, Kang H, Kiesss A, et al.  A phase I Study of Afatinib/Carboplatin/Paclitaxel Induction Chemotherapy Followed by Standard Chemoradiation in HPV-Negative or High-Risk HPV-Positive Locally Advanced-Stage II/IVa/IVb HNSCC.  J Natl Compr Canc Netw 5.5, 2015 (Abstract AB2015-3). 
http://www.jnccn.org/content/13/5S/619.full

Fury M, Xiao H,. Baxi S, et al. A phase II trial of temsirolimus + low dose weekly carboplatin and paclitaxel for recurrent/ metastatic HNSCC. Clin Oncol 32:5s, 2014 (suppl; abstr 6019) 
http://meetinglibrary.asco.org/content/133704-144

Sacco A, Zhao L, Carey R, et al. Phase II trial evaluating axitinib for patients with unresectable, recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). J Clin Oncol 32, 2014 (suppl; abstr e17027) 
http://meetinglibrary.asco.org/content/126335-144

Fury MG, Sherman EJ, Rao SS, et al. Phase I study of weekly albumin-bound paclitaxel (ab-P) plus weekly cetuximab (Cet) plus intensity-modulated radiation therapy (IMRT) in patients with stage III/IVb head and neck squamous cell carcinoma (HNSCC). J Clin Oncol 2013;31:Abstract 6034.
http://meetinglibrary.asco.org/content/110307-132

Teknos TN, Old M, Ozer E, et al. A phase I trial of vorinostat in combination with standard chemoradiation therapy in advanced oropharyngeal squamous cell carcinoma: preliminary results. J Natl Compr Canc Netw 2013;11:Abstract 2013–14.
http://www.jnccn.org/content/11/4/373.full

Khushalani NI, Yang G, Tan W, et al.  Gene expression profile (GEP) for the prediction of pathologic complete response (pCR): Preliminary data from a neoadjuvant study of capecitabine (C), oxaliplatin (OXP), and radiation (RT) for esophageal cancer (EC).  J Clin Oncol 2010;28(Suppl 15):Abstract 4100.
http://meeting.ascopubs.org/gca?allch=&submit=Go&gca=ascomtg%3B28%2F15_suppl%2F4100


Hepatocellular Carcinoma

Abou-Alfa G, Capanu M, Lowery M, et al.  First stage results of a second line phase II trial of sorafenib plus doxorubicin (SD) in patients (pts) with advanced hepatocellular carcinoma (HCC) who progressed on sorafenib (S).  J Clin Oncol 33, 2015 (suppl; abstr e15147). 
http://abstracts.asco.org/156/AbstView_156_149099.html

Kelley R, Nimeiri H, Gordan J, et al. Phase II trial of temsiroliums (TEM) plus sorafenib (SOR) in hepatocellular carcinoma (HCC).  J Clin Oncol 33, 2015 (suppl 3; abstr TPS501)
http://meetinglibrary.asco.org/content/140201-158

Kelley RK, Nimeiri HS, Munster PN, et al.  Phase I trial of temsirolimus (TEM) plus sorafenib (SOR) in advanced hepatocellular carcinoma (HCC) with pharmacokinetic (PK) and biomarker correlates [abstract].  J Clin Oncol 2012;30:Abstract 4102. 
http://meeting.ascopubs.org/gca?allch=&submit=Go&gca=ascomtg%3B30%2F15_suppl%2F4102

Kelley RK, Nimeiri HS, Vergo, MT, et al.  Phase I trial of temsirolimus (TEM) plus sorafenib (SOR) in advanced hepatocellular carcinoma (HCC) [abstract].  J Clin Oncol 2011;29(Suppl 4):Abstract 296. 
http://meeting.ascopubs.org/gca?allch=&submit=Go&gca=ascomtg%3B29%2F4_suppl%2F296

Fu S, Naing A, Moulder SL, et al.  A phase I study of hepatic arterial infusion of nab-paclitaxel in patients with predominant hepatic metastases [abstract].  J Clin Oncol 2010;28:Abstract e13044.
http://meeting.ascopubs.org/gca?allch=&submit=Go&gca=ascomtg%3B28%2F15_suppl%2Fe13044

Kelley RK, Nimeiri HS, Vergo MT, et al.  A phase I trial of the combination of temsirolimus (TEM) and sorafenib (SOR) in advanced hepatocellular carcinoma (HCC) [abstract].  J Clin Oncol 2010;28(Suppl 15):Abstract TPS213.
http://meeting.ascopubs.org/gca?allch=&submit=Go&gca=ascomtg%3B28%2F15_suppl%2FTPS213


Lung Cancer

Mehra R, Turaka A, Meyer J, et al.  Phase I study of vorinostat with concurrent chemoradiotherapy (CRT) for locally advanced non-squamous non-small cell lung cancer (NSCLC) (NCT01059552).  J Clin Oncol 33, 2015 (suppl; abstr 7553).  http://abstracts.asco.org/156/AbstView_156_152506.html

Bertino EM, Williams TM, Shilo K, Villalona-Calero MA, Phillips GS, Mo X, Otterson GA. Phase II Trial of Nab-paclitaxel plus Carboplatin for Advanced NSCLC in Patients at Risk of Bleeding from VEGF Directed Therapies. 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology; Poster Presentation No. 193. http://www.abstractsonline.com/plan/ViewAbstract.aspx?mID=3554&sKey=2c699338-22f5-4077-afae-7fe885faf178&cKey=919914be-3050-49c6-8db1-943f0eb12621&mKey=10928699-1c60-400f-ac5f-efac35ae369e

Mehra R, Turaka A, Meyer J, et al.  Phase I study of vorinostat with concurrent chemoradiotherapy (CRT) for locally advanced nonsquamous non-small cell lung cancer (NSCLC).  J Natl Compr Canc Netw 2013;11:Abstract 2013–1.
http://www.jnccn.org/content/11/3/240.extract

Bertino EM, Villalona-Calero MA, Nana-Sinkam P, et al.  Phase 2 Trial of nab-paclitaxel plus carboplatin for advanced NSCLC in patients at risk of bleeding from VEGF directed therapies [abstract].  Cancer Res 2012;72(Suppl 1):Abstract LB-225.  http://cancerres.aacrjournals.org/gca?gca=canres%3B72%2F8_Supplement%2FLB-225&allch=&submit=Go

Otterson GA, Nana-Sinkam P, Crawford M, et al. Blood based miRNA analysis from a phase 2 trial of nab-paclitaxel plus carboplatin for advanced NSCLC in patients ineligible for bevacizumab. J Thorac Oncol 2012; 7(15): Abstract 1004. http://journals.lww.com/jto/Fulltext/2012/09004/Abstracts.5.aspx

Otterson GA, Bertino EM, Karim NA, et al. Phase II trial of nab-paclitaxel plus carboplatin for advanced NSCLC in patients at risk of bleeding from VEGF directed therapies. Journal of Thoracic Oncology. 14th World Conference on Lung Cancer, Volume 6, Number 6, Supplement 2, June 2011.
http://journals.lww.com/jto/toc/2011/06002

Bertino EM, Otterson GA, Villalona-Calero MA, et al.  Phase II trial of nab-paclitaxel plus carboplatin for advanced NSCLC in patients at risk of bleeding from VEGF-directed therapies [abstract].  J Clin Oncol 2010;28(Suppl 15):Abstract TPS291.
http://meeting.ascopubs.org/gca?allch=&submit=Go&gca=ascomtg%3B28%2F15_suppl%2FTPS291


Melanoma

Daud A, Chapman P, Kadafour M, et al.  Phase II trial of trametinib in combination with the AKT inhibitor GSK 2141795 in BRAF wild-type melanoma.  J Clin Oncol 33, 2015 (suppl; abstr 9068). 
http://abstracts.asco.org/156/AbstView_156_152674.html

Mehra R, Turaka A, Meyer J, et al.  Phase I study of vorinostat with concurrent chemoradiotherapy (CRT) for locally advanced non-squamous non-small cell lung cancer (NSCLC)  (NCT01059552).  J Clin Oncol 33, 2015 (suppl; abstr 7553).  http://abstracts.asco.org/156/AbstView_156_152506.html

Khushalani N; Miller A; Adjei A et al.  Predictive Markers of Response in a Phase II Trial of Axitinib in Advanced Melanoma.  J Natl Compr Canc Netw 2014; 12:455-462 (#AB2014.22).  http://www.jnccn.org/content/12/4/455.full

Graf D, Khushalani N, Miller A et al.  Response assessment using [18F]-fluorothymidine-positron emission tomography (FLT-PET) in a phase II trial of axitinib in advanced melanoma.  J Nucl Med. 2014; 55 (Supplement 1):1685.  
http://jnumedmtg.snmjournals.org/cgi/content/short/55/1_MeetingAbstracts/1685


Peritoneal Cancer

Cristea M, Synold T, Frankel P, et al.  Significant Pharmacologic Advantage (PA) of Intraperitoneal (IP) nab-Paclitaxel in Patients with Advanced Malignancies Primarily Confined to the Peritoneal Cavity.  J Clin Oncol 33, 2015 (suppl; abstr 2553).  http://abstracts.asco.org/156/AbstView_156_152193.html

Cristea MC, Rivkin S, Lim D, et al.  Phase I Trial of IP nab-Paclitaxel in Advanced Cancer Confined to the Peritoneal Cavity. ESMO 2014, 27.09.2014, 12:45 - 13:45.
https://www.webges.com/cslide/library/esmo/browse/search/j3a#9faC03it


Prostate Cancer

Zollinger L, Morton K, Agarwal N, et al. 18F-FDG and FLT PET for early prediction of response to sunitinib in metastatic renal cell carcinoma. J Nucl Med 2013;54(Suppl 2):Abstract 1605.
http://jnumedmtg.snmjournals.org/cgi/content/meeting_abstract/54/2_MeetingAbstracts/1605

Armstrong A, Shen T, Halabi S, et al.  Phase 2 trial of temsirolimus in men with castration-resistant metastatic prostate cancer [abstract].  J Clin Oncol 2013;31(Suppl 6):Abstract 105.
http://meetinglibrary.asco.org/content/106159-134

Armstrong AJ, Kemeny G, Turnbull JD, et al. Impact of temsirolimus and anti-androgen therapy on circulating tumor cell (CTC) biology in men with castration-resistant metastatic prostate cancer (CRPC): A phase II study. J Clin Oncol 2010;28(Suppl 15):Abstract TPS249.
http://meetinglibrary.asco.org/content/47821-74


Renal Cell Cancer

Zollinger L, Morton M, Agarwal N, et al. 18F-FDG and FLT PET for early prediction of response to Sunitinib in metastatic renal cell carcinoma. J Nucl Med 2013;54(Suppl 2):Abstract 1605  http://jnumedmtg.snmjournals.org/cgi/content/short/54/2_MeetingAbstracts/1605

Bhatt R, Wang X, Zhang L, et al.  Cox-2 inhibition delays resistance to sunitinib in RCC xenograft models [abstract].  AACR Meeting Abstracts 2009:Abstract 153.
http://www.aacrmeetingabstracts.org/cgi/content/meeting_abstract/2009/2_Annual_Meeting/153?maxtoshow=&hits=10&RESULTFORMAT=&author1=mier&fulltext=Sunitinib+&andorexactfulltext=and&searchid=1&FIRSTINDEX=0&sortspec=relevance&resourcetype=HWCIT

Yoon JL, Stangenberg L, Rothrock C, et al.  Efficacy of sunitinib with and without radiation therapy in a genetically engineered mouse model of sarcoma [abstract].  AACR Meeting Abstracts 2008:Abstract 1319.
http://www.aacrmeetingabstracts.org/cgi/content/meeting_abstract/2008/1_Annual_Meeting/1319?maxtoshow=&hits=10&RESULTFORMAT=1&author1=yoon&andorexacttitle=and&titleabstract=sunitinib+&andorexacttitleabs=and&searchid=1&FIRSTINDEX=0&sortspec=relevance&fdate=1/1/2004&tdate=12/31/2010&resourcetype=HWCIT

Bhatt R, Zhang L, Schor-Bardach R, et al.  Effects of sorafenib administration on the IFN signaling pathway and on the expression of IFN-inducible genes in RCC tumor cells [abstract].  AACR Meeting Abstracts 2008:Abstract 1128.
http://www.aacrmeetingabstracts.org/cgi/content/meeting_abstract/2008/1_Annual_Meeting/1128?maxtoshow=&hits=10&RESULTFORMAT=&author1=mier&fulltext=Sunitinib+&andorexactfulltext=and&searchid=1&FIRSTINDEX=0&sortspec=relevance&resourcetype=HWCIT

Kumar M, Panka D, Bhatt R, et al.  Mechanism of acquired resistance to sunitinib in RCC [abstract].  AACR Meeting Abstracts 2008:Abstract 1127.
http://www.aacrmeetingabstracts.org/cgi/content/meeting_abstract/2008/1_Annual_Meeting/1127?maxtoshow=&hits=10&RESULTFORMAT=&author1=mier&fulltext=Sunitinib+&andorexactfulltext=and&searchid=1&FIRSTINDEX=0&sortspec=relevance&resourcetype=HWCI


Sarcoma

Eroglu Z, Tawbi H, Hu J, et al. A Randomized Phase II trial of AZD6244 alone and AZD6244 plus Temsirolimus for Soft-Tissue Sarcomas. J Clin Oncol 32:5s, 2014 (suppl; abstr 10526)
http://meetinglibrary.asco.org/content/132917-144

Loeb DM, DeLorenzo KA, Chen ARS, et al.  A dose-finding study of temsirolimus and liposomal doxorubicin for patients with advanced soft tissue or bone sarcoma [abstract].  J Clin Oncol 2011;29:Abstract 10026. 
http://meeting.ascopubs.org/gca?allch=&submit=Go&gca=ascomtg%3B29%2F15_suppl%2F10026


Solid Tumor

Shah MH, Phelps MA, Poi M, et al.  A phase I trial of dabrafenib (BRAF inhibitor) and pazopanib in BRAF mutated advanced malignancies. J Clin Oncol 32:5s, 2014 (suppl; abstr TPS2628).
http://meetinglibrary.asco.org/content/128734-144

Azad N, Ball D, Sherman S, et al.  A phase I study determining the safety and tolerability of combination therapy with Pazopanib (P), a VEGFR/PDGFR/Raf inhibitor, and GSK1120212 (Trametinib: T), a MEK inhibitor, in advanced solid tumors with expansion cohorts in advanced differentiated thyroid cancer (DTC), cholangiocarcinoma (ChCA), and soft tissue sarcoma (STS). Mol Cancer Ther 2013;12(11 Suppl):B279.
http://mct.aacrjournals.org/content/12/11_Supplement/B279.short

Becher O, Gilheeney S, Khakoo Y, et al.  Phase I study of perifosine (AKT inhibitor) and temsirolimus (mTOR inhibitor) for recurrent pediatric solid tumors. Neuro-Oncology 13:i1–i37, 2011.  doi:10.1093/neuonc/nor018 (suppl abstract 0120) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3084183

Saif MW, Sellers S, Li M, et al.  A Phase I study of bi-weekly administration of 24-hr Gemcitabine (GEM) followed by 24-hr Irinotecan (CPT-11) in patients with solid tumors.  J Clin Oncol 2005;23(Suppl 16):Abstract 2102. 
http://meeting.ascopubs.org/gca?allch=&submit=Go&gca=ascomtg%3B23%2F16_suppl%2F2102


Thyroid Cancer

Sherman EJ, Ho A, Fury MG, et al.  A phase II study of temsirolimus/sorafenib in patients with radioactive iodine (RAI)-refractory thyroid carcinoma [abstract].  J Clin Oncol 2012;30:Abstract 5514. 
http://meeting.ascopubs.org/gca?allch=&submit=Go&gca=ascomtg%3B30%2F15_suppl%2F5514